96 related articles for article (PubMed ID: 2329964)
1. 2' Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: a CALGB phase II study.
Duggan DB; Anderson JR; Dillman R; Case D; Gottlieb AJ
Med Pediatr Oncol; 1990; 18(3):203-6. PubMed ID: 2329964
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease.
Cummings FJ; Kim K; Neiman RS; Comis RL; Oken MM; Weitzman SA; Mann RB; O'Connell MJ
J Clin Oncol; 1991 Apr; 9(4):565-71. PubMed ID: 2066753
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
4. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.
Mercieca J; Matutes E; Dearden C; MacLennan K; Catovsky D
J Clin Oncol; 1994 Dec; 12(12):2588-93. PubMed ID: 7989933
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group.
Monfardini S; Sorio R; Cavalli F; Cerny TH; Van Glabbeke M; Kaye S; Smyth JF
Oncology; 1996; 53(2):163-8. PubMed ID: 8604244
[TBL] [Abstract][Full Text] [Related]
6. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
9. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Dang NH; Hagemeister FB; Duvic M; Romaguera JE; Younes A; Jones D; Samuels B; Fayad LE; Pro B; Samaniego F; Sarris A; Goy A; McLaughlin P; Tong AT; Walker PL; Tiongson LP; Smith TL; Huh YO; Morimoto C; Rodriguez MA
Oncol Rep; 2003; 10(5):1513-8. PubMed ID: 12883733
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B.
Budman DR; Petroni GR; Johnson JL; Cooper MR; Schlossman DM; Barcos M; Peterson BA
J Clin Oncol; 1997 Oct; 15(10):3275-9. PubMed ID: 9336365
[TBL] [Abstract][Full Text] [Related]
11. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
12. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
13. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Younes A; Sarris A; Melnyk A; Romaguera J; McLaughlin P; Swan F; Rodriguez MA; Hagemeister F; Moore D; North L
J Clin Oncol; 1995 Mar; 13(3):583-7. PubMed ID: 7884419
[TBL] [Abstract][Full Text] [Related]
14. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515.
Golomb HM; Dodge R; Mick R; Budman D; Hutchison R; Horning SJ; Schiffer CA
Leukemia; 1994 Dec; 8(12):2037-40. PubMed ID: 7807991
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
16. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia.
Johnson SA; Catovsky D; Child JA; Newland AC; Milligan DW; Janmohamed R
Invest New Drugs; 1998; 16(2):155-60. PubMed ID: 9848579
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
Gentet JC; Patte C; Quintana E; Bergeron C; Rubie H; Pein F; Demaille MC; Philip T; Raybaud C
J Clin Oncol; 1990 Apr; 8(4):661-5. PubMed ID: 2313335
[TBL] [Abstract][Full Text] [Related]
19. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki D; Sklar J; Barcos M; Peterson BA
Leuk Lymphoma; 2001; 42(6):1255-64. PubMed ID: 11911406
[TBL] [Abstract][Full Text] [Related]
20. Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
Smith SM; Johnson JL; Niedzwiecki D; Eder JP; Canellos G; Cheson BD; Bartlett NL;
Leuk Lymphoma; 2006 Aug; 47(8):1511-7. PubMed ID: 16966261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
